Holen Sie sich die Stockscreener-App
1.23
0.82%
0.01
Handel nachbörslich:
1.27
0.04
+3.25%
Soligenix Inc Aktie (SNGX) Neueste Nachrichten
Earnings Risk: Should you avoid Soligenix Inc stock right now2026 Trends & Verified Chart Pattern Signals - baoquankhu1.vn
SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Smartkarma
Soligenix receives UK regulatory designation for Behçet’s drug By Investing.com - Investing.com Canada
Soligenix (SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behcet Disease - NewMediaWire
Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease - TipRanks
Soligenix receives UK regulatory designation for Behçet’s drug - Investing.com
Soligenix (SNGX) Receives UK Nod for Innovative Behcet's Disease Treatment - GuruFocus
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - PR Newswire
Soligenix (SNGX) Leverages Platform Science for Broader Therapeutic Reach - NewMediaWire
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - TradingView
SNGX Earnings History & Surprises | EPS & Revenue Results | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
SNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behcet Disease - Digital Journal
Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit - Digital Journal
Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology - Digital Journal
SNGX Should I Buy - Intellectia AI
Soligenix receives positive EMA opinion for orphan drug status - Investing.com Australia
Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA). - Bitget
Soligenix receives positive EMA opinion for orphan drug status By Investing.com - Investing.com UK
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - Nasdaq
SNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Growth Value: Is Soligenix Inc a speculative investmentOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Soligenix to Present at BIO Investment Summit - Intellectia AI
Soligenix to Present at BIO Investment & Growth Summit - PR Newswire
SNGX PE Ratio & Valuation, Is SNGX Overvalued - Intellectia AI
Will Soligenix Inc. face regulatory challenges2025 Stock Rankings & Proven Capital Preservation Methods - mfd.ru
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Armistice Capital and Steven Boyd report 4.99% stake in Soligenix (SNGX) - Stock Titan
Why Soligenix Inc. stock is favored by top institutions2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Soligenix, Inc. Announces Adjournment of Annual Meeting, Informa - GuruFocus
Will Soligenix Inc. stock split attract more investors2025 Geopolitical Influence & AI Forecasted Stock Moves - mfd.ru
Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX) - The Globe and Mail
Soligenix Provides Shareholder Update on Rare Disease Pipeline - TipRanks
Will Soligenix Inc. (DOA0) stock beat international competitionJuly 2025 Intraday Action & Stepwise Trade Execution Plans - mfd.ru
Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options - Digital Journal
Soligenix Details Recent Progress and Upcoming Milestones - Morningstar
Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal
Soligenix’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - The Globe and Mail
Exit Recap: Is Soligenix Inc a speculative investment2025 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
Short Interest in Soligenix Inc. (NASDAQ:SNGX) Decreases By 12.5% - Defense World
Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer - The Globe and Mail
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape - The Globe and Mail
Soligenix (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM) - Digital Journal
Soligenix Advances Novel Visible Light Therapy for Challenging Cutaneous T-cell Lymphoma - citybuzz -
Soligenix's HyBryte Therapy Shows Promise for Early-Stage Cutaneous T-Cell Lymphoma Treatment - citybuzz -
Soligenix Advances Novel Visible Light Therapy for Early-Stage Cutaneous T-Cell Lymphoma - MEXC
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):